title: Hemophagocytosis during fludarabine-based SCT for systemic juvenile idiopathic arthritis.
authors.forename: R A
authors.initials: RA
authors.lastname: Ferreira
authors.forename: S J
authors.initials: SJ
authors.lastname: Vastert
authors.forename: M
authors.initials: M
authors.lastname: Abinun
authors.forename: H E
authors.initials: HE
authors.lastname: Foster
authors.forename: C
authors.initials: C
authors.lastname: Modesto
authors.forename: T
authors.initials: T
authors.lastname: Olivé
authors.forename: W
authors.initials: W
authors.lastname: Kuis
authors.forename: N M
authors.initials: NM
authors.lastname: Wulffraat
mesh_terms: D000293:Adolescent; D001171:Arthritis, Juvenile / Q000628:therapy*; D002648:Child; D005260:Female; D006801:Humans; D008262:Macrophage Activation / Q000276:immunology; D008297:Male; D019653:Myeloablative Agonists / Q000009:adverse effects; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D013577:Syndrome; D019172:Transplantation Conditioning / Q000009:adverse effects* / Q000379:methods; D014182:Transplantation, Autologous; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D019653:Myeloablative Agonists; D014740:Vidarabine; C024352:fludarabine